论文部分内容阅读
本文报告以西艾克(VDS)为主联合化疗治疗中晚期肺癌20例。结果总有效率为50.0％,其中小细胞肺癌有效率为75.0％,非小细胞肺癌有效率为41.7％(肺腺癌为42.9％,肺鳞癌为40.0％);转移性肺癌有效率为50.0％。作者认为含有VDS联合化疗方案对抗癌药不敏感的NSCLC特别是对治疗效果差的肺腺癌有较好疗效。VDS神经毒性较轻,骨髓抑制是其剂量限制性毒性,应加强防治以提高疗效。
This report reports that 20 patients with advanced lung cancer were treated with VDS-based chemotherapy. Results The total effective rate was 50.0%, of which the effective rate of small cell lung cancer was 75.0%, the effective rate of non-small cell lung cancer was 41.7% (42.9% for lung adenocarcinoma and 40.0% for squamous cell carcinoma of lung); the effective rate for metastatic lung cancer was 50.0. %. The authors believe that NSCLC with VDS combined with chemotherapy regimens that are not sensitive to anticancer drugs is particularly effective for poorly treated lung adenocarcinomas. VDS has less neurotoxicity and myelosuppression is its dose-limiting toxicity. Prevention and treatment should be strengthened to improve efficacy.